High-resolution genomic analysis: The tumor-immune interface comes into focus

Genome Biology

Volumn 16, Issue 1, 2015, Pages

  Havel, Jonathan J ^a   Chan, Timothy A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL MATURATION ANTIGEN; CHEMOKINE RECEPTOR CCR8; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANTIGENICITY; ARTICLE; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; COLORECTAL CANCER; COLORECTAL TUMOR; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; OVERALL SURVIVAL; PHENOTYPE; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; COLORECTAL NEOPLASMS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; PATHOLOGY;

ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; TUMOR ESCAPE;

EID: 84939166449     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-015-0631-3     Document Type: Article

References (10)

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
2. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015. doi:10.1200/JCO.2014.56.6018.
3. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al. Characterization of the immunophenotypes and the antigenomes reveal distinct tumor escape mechanisms and novel targets for immunotherapy of colorectal cancers. Genome Biol. 2015;16:620.
4. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782-95.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4.
6. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51.
7. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102:16013-18.
8. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31:e439-42.
9. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-99.
10. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641-5.